Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $41 to $46.
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $41 to $46.